Why PGD doesn't improve Success Rate in IVF?
IVF clinics often promote preimplantation genetic testing (PGT) as a way to boost pregnancy rates. While it sounds promising selecting only genetically normal embryos for implantation a deeper look reveals limitations and ethical considerations.
The PGT Promise and Its Limits:
PGT analyses a few cells biopsied from an embryo to identify chromosomal abnormalities. The goal is to transfer only healthy embryos, potentially increasing pregnancy success. However, PGT has limitations:
- Limited Scope: It primarily focuses on chromosomal issues, not all potential genetic defects. An embryo might appear normal through PGT but still have other problems.
- Sampling Issues: The biopsied cells might not represent the entire embryo. Mosaicism, where some cells are abnormal and others are healthy, can lead to inaccurate results.
- Embryonic Resilience: Embryos can self-correct. Even if a biopsy reveals abnormalities, the embryo might develop into a healthy baby.
Ethical Concerns: Transparency Matters
There are concerns about clinics downplaying PGT's limitations to push an expensive procedure. Patients deserve transparency to make informed decisions.
Alternatives: A broader perspective
Standard prenatal tests like NIPT or amniocentesis offer a more comprehensive genetic picture after pregnancy is established. These tests analyse a larger sample of foetal cells, providing a more reliable assessment.
The takeaway: informed choices for success.
The decision to undergo PGT should be well-informed and made with a trusted doctor who discusses both benefits and limitations. Weigh the costs against the uncertain impact on pregnancy success. PGT is just one piece of the puzzle. A holistic approach that considers factors like age, ovarian reserve, and overall health is crucial for a successful IVF journey. By understanding PGT's true potential, patients can navigate the world of IVF with greater clarity and make informed choices aligned with their needs and goals.